Blue­bird hopes to raise up­wards of $100M by sell­ing shares

Blue­bird bio is look­ing for cash.

Wednes­day morn­ing, the gene ther­a­py biotech an­nounced that it was look­ing to sell 20 mil­lion shares of its stock $BLUE, which at Tues­day’s clos­ing price of $7.28, would trans­late to rough­ly $145 mil­lion. In ad­di­tion, as part of the of­fer­ing, un­der­writ­ers — in­clud­ing Gold­man Sachs and JP Mor­gan — can buy an ad­di­tion­al 3 mil­lion shares of stock, which would be around an­oth­er $20 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER